FA
ABBV icon

FMA Advisory’s AbbVie ABBV Stock Holding History

FMA Advisory’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$2.35M Sell
21,766
-439
-2% -$50.2K 0.88% 39
2021
Q2 		$2.5M Buy
22,205
+1,337
+6% +$151K 0.93% 39
2021
Q1 		$2.26M Buy
20,868
+367
+2% +$39.3K 0.7% 53
2020
Q4 		$2.2M Buy
20,501
+4,242
+26% +$408K 0.73% 46
2020
Q3 		$1.42M Buy
16,259
+3,418
+27% +$322K 0.57% 60
2020
Q2 		$1.26M Buy
12,841
+53
+0.4% +$4.67K 0.57% 62
2020
Q1 		$974K Buy
12,788
+274
+2% +$23.3K 0.53% 61
2019
Q4 		$1.11M Buy
12,514
+913
+8% +$75.8K 0.45% 72
2019
Q3 		$878K Buy
11,601
+999
+9% +$68.5K 0.38% 78
2019
Q2 		$771K Sell
10,602
-673
-6% -$52.9K 0.34% 82
2019
Q1 		$909K Sell
11,275
-352
-3% -$28.8K 0.42% 75
2018
Q4 		$1.07M Buy
11,627
+125
+1% +$11K 0.55% 57
2018
Q3 		$1.09M Buy
11,502
+113
+1% +$10.7K 0.49% 67
2018
Q2 		$1.05M Buy
11,389
+36
+0.3% +$3.52K 0.5% 64
2018
Q1 		$1.07M Sell
11,353
-1,226
-10% -$135K 0.52% 65
2017
Q4 		$1.22M Buy
12,579
+1,216
+11% +$115K 0.57% 58
2017
Q3 		$1.01M Sell
11,363
-87
-0.8% -$6.62K 0.59% 55
2017
Q2 		$830 Buy
11,450
+587
+5% +$39.5K 0.43% 56
2017
Q1 		$708K Buy
+10,863
New +$683K 0.36% 78
2015
Q2 		$694K Buy
+10,326
New +$674K 0.43% 65
2014
Q4 		$1.45M Sell
22,121
-129
-0.6% -$8.13K 0.5% 82
2014
Q3 		$1.28M Buy
22,250
+139
+0.6% +$7.72K 0.47% 84
2014
Q2 		$1.25M Sell
22,111
-111
-0.5% -$5.82K 0.46% 88
2014
Q1 		$1.14M Buy
22,222
+919
+4% +$46.4K 0.45% 87
2013
Q4 		$1.13M Buy
21,303
+19
+0.1% +$934 0.46% 86
2013
Q3 		$952K Sell
21,284
-248
-1% -$11K 0.38% 93
2013
Q2 		$890K Buy
+21,532
New +$942K 0.38% 93

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

FMA Advisory's ABBV Position: Q3 2021 in Review

FMA Advisory reduced its AbbVie (ABBV) stake by 2% in Q3 2021, selling an estimated $50.2K and leaving 21,766 shares worth $2.35M. The position accounts for 0.88% of the portfolio, ranked #39.

FMA Advisory first reported a position in ABBV in Q2 2013 and has held it in 27 quarters since. The position peaked at $2.5M in Q2 2021. 2,654 funds tracked by Wall St. Rank hold ABBV as of Q3 2021.

  • FMA Advisory held 21,766 shares of AbbVie worth $2.35M as of Q3 2021.
  • FMA Advisory sold 439 AbbVie shares in Q3 2021, an estimated $50.2K.
  • AbbVie made up 0.88% of FMA Advisory's portfolio in Q3 2021, its #39 holding.
  • FMA Advisory first reported a position in AbbVie in Q2 2013 and has held it in 27 quarters since.
  • FMA Advisory's AbbVie position peaked at $2.5M in Q2 2021.
  • 2,654 funds tracked by Wall St. Rank held AbbVie as of Q3 2021.

Based on FMA Advisory's 13F filing for Q3 2021, filed 15 Nov 2021.